US Pharma MarketingOSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win
OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
Source: FierceBiotech